ALVR AlloVir

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET.

A live webcast and archived replay of the presentation will be available on the Investors & Press section of the AlloVir website at .

About AlloVir

AlloVir is a leading late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's innovative and proprietary technology platform leverages off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit or follow us on or .

EN
16/11/2023

Underlying

ALVRAlloVir

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AlloVir

 PRESS RELEASE
Free
ALVR ALLOVIR

Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equit...

Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference. The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience.  Details: ...

June 2, 2025 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

Kalaris to Participate at Stifel Ophthalmology Forum

Kalaris to Participate at Stifel Ophthalmology Forum PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate at an upcoming Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum. Details: Type: Fireside ChatSpeakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical OfficerDate: Tuesday, May 27th, 2025Time: 08:00 am ETLoca...

May 23, 2025 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

Kalaris Reports First Quarter 2025 Financial Results and Provides Busi...

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025  Cash and cash equivalents of $101M as of March 31, 2025, expected to fund operations into Q4 2026 PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinica...

May 14, 2025 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair...

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth PALO ALTO, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Leone Patterson to its Board of Directors and as Chair of the Board’s Audit Committee. “We’re delighted to...

April 4, 2025 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

Kalaris Announces Closing of Merger with AlloVir

Kalaris Announces Closing of Merger with AlloVir Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina Currently enrolling nAMD patients in a Phase 1 trial, with initial data from Part 1 of the trial expected in the second half of 2025 Post-transaction cash of approximately $100 million expected to fund operations into the fourth quarter of 2026 Shares expected to trade on Nasdaq under “KLRS”, effective March 19, 2025 ...

March 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch